PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - NYSE:PBH - US74112D1019 - Common Stock
62.03 USD
-0.38 (-0.61%)
62.03 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to PBH. PBH was compared to 192 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making PBH a very profitable company, without any liquidiy or solvency issues. PBH has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year PBH was profitable.
PBH had a positive operating cash flow in the past year.
Of the past 5 years PBH 4 years were profitable.
Each year in the past 5 years PBH had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 6.21%, PBH belongs to the best of the industry, outperforming 90.63% of the companies in the same industry.
PBH has a better Return On Equity (11.48%) than 87.50% of its industry peers.
The Return On Invested Capital of PBH (7.95%) is better than 85.42% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PBH is significantly below the industry average of 15.41%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROIC | 7.95% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
With an excellent Profit Margin value of 19.02%, PBH belongs to the best of the industry, outperforming 93.23% of the companies in the same industry.
PBH's Profit Margin has improved in the last couple of years.
PBH has a Operating Margin of 31.15%. This is amongst the best in the industry. PBH outperforms 94.79% of its industry peers.
PBH's Operating Margin has been stable in the last couple of years.
PBH has a better Gross Margin (56.13%) than 66.15% of its industry peers.
PBH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
PBH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for PBH has been reduced compared to 1 year ago.
The number of shares outstanding for PBH has been reduced compared to 5 years ago.
PBH has a better debt/assets ratio than last year.
2.2 Solvency
PBH has an Altman-Z score of 2.61. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
PBH has a Altman-Z score of 2.61. This is in the better half of the industry: PBH outperforms 68.23% of its industry peers.
The Debt to FCF ratio of PBH is 3.79, which is a good value as it means it would take PBH, 3.79 years of fcf income to pay off all of its debts.
PBH's Debt to FCF ratio of 3.79 is amongst the best of the industry. PBH outperforms 87.50% of its industry peers.
PBH has a Debt/Equity ratio of 0.55. This is a neutral value indicating PBH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.55, PBH is not doing good in the industry: 63.54% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Altman-Z | 2.61 |
ROIC/WACC0.96
WACC8.27%
2.3 Liquidity
A Current Ratio of 4.38 indicates that PBH has no problem at all paying its short term obligations.
PBH has a better Current ratio (4.38) than 65.63% of its industry peers.
A Quick Ratio of 2.99 indicates that PBH has no problem at all paying its short term obligations.
The Quick ratio of PBH (2.99) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 14.21% over the past year.
PBH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.88% yearly.
The Revenue has been growing slightly by 0.63% in the past year.
PBH shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.39% yearly.
EPS 1Y (TTM)14.21%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%5.56%
Revenue 1Y (TTM)0.63%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-6.59%
3.2 Future
Based on estimates for the next years, PBH will show a small growth in Earnings Per Share. The EPS will grow by 3.32% on average per year.
PBH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.15% yearly.
EPS Next Y1.73%
EPS Next 2Y3.24%
EPS Next 3Y2.71%
EPS Next 5Y3.32%
Revenue Next Year-2.19%
Revenue Next 2Y0.04%
Revenue Next 3Y0.52%
Revenue Next 5Y1.15%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 13.54, the valuation of PBH can be described as correct.
PBH's Price/Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 88.54% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.00, PBH is valued a bit cheaper.
With a Price/Forward Earnings ratio of 12.85, PBH is valued correctly.
PBH's Price/Forward Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 83.33% of the companies in the same industry.
PBH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.87, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.54 | ||
| Fwd PE | 12.85 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 88.02% of the companies listed in the same industry.
PBH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PBH is cheaper than 89.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.4 | ||
| EV/EBITDA | 10.37 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)7.85
PEG (5Y)1.52
EPS Next 2Y3.24%
EPS Next 3Y2.71%
5. Dividend
5.1 Amount
No dividends for PBH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
62.03
-0.38 (-0.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners107.07%
Inst Owner Change0.66%
Ins Owners1.29%
Ins Owner Change5.74%
Market Cap3.05B
Revenue(TTM)1.12B
Net Income(TTM)213.00M
Analysts84.44
Price Target85.27 (37.47%)
Short Float %3.39%
Short Ratio3.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.66%
Min EPS beat(2)-5.96%
Max EPS beat(2)0.64%
EPS beat(4)2
Avg EPS beat(4)-0.37%
Min EPS beat(4)-5.96%
Max EPS beat(4)4.3%
EPS beat(8)4
Avg EPS beat(8)-1.59%
EPS beat(12)7
Avg EPS beat(12)-47.18%
EPS beat(16)11
Avg EPS beat(16)-34.2%
Revenue beat(2)1
Avg Revenue beat(2)-1.94%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)1.46%
Revenue beat(4)2
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)1.46%
Revenue beat(8)3
Avg Revenue beat(8)-0.96%
Revenue beat(12)5
Avg Revenue beat(12)-0.52%
Revenue beat(16)9
Avg Revenue beat(16)0.45%
PT rev (1m)0%
PT rev (3m)-7.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-18.97%
EPS NY rev (1m)0.79%
EPS NY rev (3m)-4.35%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)-11.86%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)-3.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.54 | ||
| Fwd PE | 12.85 | ||
| P/S | 2.73 | ||
| P/FCF | 11.4 | ||
| P/OCF | 11.07 | ||
| P/B | 1.65 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.37 |
EPS(TTM)4.58
EY7.38%
EPS(NY)4.83
Fwd EY7.78%
FCF(TTM)5.44
FCFY8.77%
OCF(TTM)5.6
OCFY9.03%
SpS22.76
BVpS37.71
TBVpS-19.66
PEG (NY)7.85
PEG (5Y)1.52
Graham Number62.33
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROCE | 10.5% | ||
| ROIC | 7.95% | ||
| ROICexc | 8.3% | ||
| ROICexgc | 73.5% | ||
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% | ||
| FCFM | 23.91% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score8
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Debt/EBITDA | 2.67 | ||
| Cap/Depr | 26.62% | ||
| Cap/Sales | 0.71% | ||
| Interest Coverage | 7.65 | ||
| Cash Conversion | 72.82% | ||
| Profit Quality | 125.75% | ||
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 | ||
| Altman-Z | 2.61 |
F-Score8
WACC8.27%
ROIC/WACC0.96
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.21%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%5.56%
EPS Next Y1.73%
EPS Next 2Y3.24%
EPS Next 3Y2.71%
EPS Next 5Y3.32%
Revenue 1Y (TTM)0.63%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-6.59%
Revenue Next Year-2.19%
Revenue Next 2Y0.04%
Revenue Next 3Y0.52%
Revenue Next 5Y1.15%
EBIT growth 1Y5.97%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year7.03%
EBIT Next 3Y3.43%
EBIT Next 5Y2.94%
FCF growth 1Y26.73%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y25.6%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PBH.
What is the valuation status for PBH stock?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
How profitable is PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
How financially healthy is PRESTIGE CONSUMER HEALTHCARE?
The financial health rating of PRESTIGE CONSUMER HEALTHCARE (PBH) is 7 / 10.
What is the earnings growth outlook for PRESTIGE CONSUMER HEALTHCARE?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.73% in the next year.